Prof. Dr.Alper Sevinç

  • İlgi Alanları
  • Meme kanseri
  • Akciğer kanseri
  • Kolorektal kanserler
  • Jinekolojik kanserler
  • Kemoterapi
  • Multidisipliner tedavi yönetimi
  • İmmünoterapi
  • Genetik profilleme

Eğitim ve Uzmanlık
1990 - 1997:Marmara Üniversitesi Tıp Fakültesi – Tıp eğitimi
1998 - 2002: Malatya İnönü Üniversitesi İç Hastalıkları ABD Uzmanlık
2002 - 2006 Gaziantep Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Yan Dal Uzmanlığı

Deneyim
1998 - 2002: Malatya İnönü Üniversitesi İç Hastalıkları Asistan Dr.
2002 - 2016Gaziantep Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Prof. Dr.
2006 - 2011 Gaziantep Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Doç. Dr.
2011 - 2016 Gaziantep Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Prof. Dr.
2016 - Günümüz Medical Park Gaziantep Hastanesi

1. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group.

Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.

 

2. A national, multicenter, non-interventional, observational study on treatment patterns in patients with metastatic renal cell carcinoma in Turkey - NOTES study.

Yalçın Ş, Yildiz R, Dane F, Karaoğlu A, Öksüzoğlu B, Özyılkan Ö, Sevinç A, Özdemir F, Turna H, Uslu R, Ulay E.

Onco Targets Ther. 2018 Mar 5;11:1223-1228. doi: 10.2147/OTT.S148917. eCollection 2018.

 

3. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.

Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group.

Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16.

 

4. A hundred years after the first article, a recollection: Cabot ring.

Erdem N, Berber İ, Aydoğdu İ, Sevinç A.

Korean J Intern Med. 2016 Jan;31(1):199. doi: 10.3904/kjim.2016.31.1.199. Epub 2015 Dec 28.

 

5. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.

Aktas G, Kus T, Emin Kalender M, Kervancioglu S, Sevinc A, Kul S, Camci C.

J BUON. 2017 Jan-Feb;22(1):150-156.

 

6. Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia.

Sevinç A, Özkan M, Özet A, Dane F, Öksüzoğlu B, Işıkdoğan A, Özdemir F, Uncu D, Gümüş M, Evrensel T, Yaren A, Kara O, Tekin SB.

Onco Targets Ther. 2018 Jan 18;11:419-426. doi: 10.2147/OTT.S106342. eCollection 2018.

 

 

7. Aggressive course in a patient with mucin-producing urothelial-type adenocarcinoma of the prostate: A case report and review of the literature.

Solakhan M, Erturhan MS, Sevinç A, Çetin S.

Turk J Urol. 2018 Dec 19;45(Supp. 1):S135-S138. doi: 10.5152/tud.2018.30837. Print 2019 Nov.

 

8. Renal cell cancer: overview of the current therapeutic landscape.

Erman M, Benekli M, Basaran M, Bavbek S, Buyukberber S, Coskun U, Demir G, Karabulut B, Oksuzoglu B, Ozkan M, Sevinc A, Yalcin S.

Expert Rev Anticancer Ther. 2016 Sep;16(9):955-68. doi: 10.1080/14737140.2016.1222908. Epub 2016 Aug 24.

 

9. Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study.

Aktas G, Kus T, Kalender ME, Sevinc A, Camci C, Kul S.

Onco Targets Ther. 2016 Apr 1;9:1921-6. doi: 10.2147/OTT.S101390. eCollection 2016.

 

10. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.

Kus T, Aktas G, Kalender ME, Sevinc A, Camci C.

J Gastrointest Cancer. 2017 Jun;48(2):170-175. doi: 10.1007/s12029-016-9880-y.

 

11. Pulsed radiofrequency treatment of piriformis syndrome in a pregnant patient with malignant mesenchymal tumor.

Pirbudak L, Sevinç A, Kervancıoğlu S, Kervancıoğlu P, Ateş D.

Agri. 2016 Oct;28(4):194-198. doi: 10.5505/agri.2015.32657.

 

12. Efficacy of venlafaxine for the relief of taxane and oxaliplatin-induced acute neurotoxicity: a single-center retrospective case-control study.

Kus T, Aktas G, Alpak G, Kalender ME, Sevinc A, Kul S, Temizer M, Camci C.

Support Care Cancer. 2016 May;24(5):2085-2091. doi: 10.1007/s00520-015-3009-x. Epub 2015 Nov 7

 

13. Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study.

Oruc Z, Kaplan MA, Geredeli C, Yildirim Sari N, Ozaslan E, Aytekin A, Tamer Elkiran E, Koca S, Dogan M, Turan N, Yuce O, Sevinc A, Ercelep O, Isikdogan A.

 

14. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.

Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS, Molé A, Attali P, Le Boulicaut J, Vasseur B; RELIVE Investigators.

Lancet Gastroenterol Hepatol. 2019 Jun;4(6):454-465. doi: 10.1016/S2468-1253(19)30040-8. Epub 2019 Apr 4.

 

15. Middle East observational study in metastatic soft tissue sarcoma: an epidemiological study on the treatment patterns (MOON).

Memon MA, Karaca B, Aboelhassan R, Barsoum M, Erman M, Basaran M, Sevinc A, Hanene D, Slader C, Pilipovic V, Esma K, Kamel B.

J Cancer Res Clin Oncol. 2018 Nov;144(11):2219-2229. doi: 10.1007/s00432-018-2713-6. Epub 2018 Aug 13.

 

16. Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell canceR. Kus T, Aktas G, Sevinc A, Oktay C, Kalender ME, Camci C.

Mol Clin Oncol. 2016 Feb;4(2):290-292. doi: 10.3892/mco.2015.677. Epub 2015 Nov 13.

 

17. Evaluation of prognostic factors and treatment in advanced small bowel adenocarcinoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology (ASMO).

Aydin D, Sendur MA, Kefeli U, Umut Unal O, Tastekin D, Akyol M, Tanrikulu E, Ciltas A, Bala Ustaalioglu B, Sener Dede D, Esbag O, Inal A, Bilir C, Bilici A, Harputlu H, Berk V, Sevinc A, Yildirim Ozdemir N, Yildirim E, Sonkaya A, Ali Ustaoglu M, Gumus M.

J BUON. 2016 Sept-Oct;21(5):1242-1249.

 

18. Taxane-induced peripheral sensorial neuropathy in cancer patients is associated with duration of diabetes mellitus: a single-center retrospective study.

Kus T, Aktas G, Kalender ME, Sevinc A, Kul S, Suner A, Ulker E, Camci C.

Support Care Cancer. 2016 Mar;24(3):1175-9. doi: 10.1007/s00520-015-2898-z. Epub 2015 Aug 18.

 

19. Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas.

Cicin İ, Özatlı T, Türkmen E, Özturk T, Özçelik M, Çabuk D, Gökdurnalı A, Balvan Ö, Yıldız Y, Şeker M, Özdemir N, Yapar B, Tanrıverdi Ö, Günaydin Y, Menekşe S, Öksüzoğlu B, Aksoy A, Erdogan B, Bekir Hacıoglu M, Arpaci E, Sevinç A.

Balkan Med J. 2016 Sep;33(5):517-524. doi: 10.5152/balkanmedj.2016.151268. Epub 2016 Sep 1.

 

20. Effectiveness and Safety of LMWH Treatment in Patients With Cancer Diagnosed With Non-High-Risk Venous Thromboembolism: Turkish Observational Study (TREBECA).

Ozaslan E, Ozkan M, Cicin I, Benekli M, Kocer M, Uysal M, Oksuzoglu B, Isikdogan A, Cubukcu E, Elkiran ET, Dane F, Aliustaoglu M, Sevinc A, Karaoglu A, Ulas A, Gokoz-Dogu G.

Clin Appl Thromb Hemost. 2018 Sep;24(6):973-979. doi: 10.1177/1076029617753538. Epub 2018 Feb 18.

 

21. Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less.

Özaslan E, Karaca H, Koca S, Sevinç A, Hacioğlu B, Özkan M, Özçelik M, Duran AO, Hacibekiroğlu İ, Yildiz Y, Tanriverdi Ö, Menekşe S, Aksoy A, Bozkurt O, Urvay S, Uysal M, Demir H, Çiltaş A, Dane F.

Anticancer Drugs. 2017 Feb;28(2):222-229. doi: 10.1097/CAD.0000000000000445.

 

22. Effectiveness and safety of cabazitaxel chemotherapy for metastatic castration-resistant prostatic carcinoma on Turkish patients (The Anatolian Society of Medical Oncology).

Süner A, Aydın D, Hacıoğlu MB, Doğu GG, İmamoğlu GI, Menekşe S, Pilancı KN, Yazıcı ÖK, Koca D, Karaağaç M, Akyol M, Akman T, Ergen S, Avcı N, Kaçan T, Bozkurt O, Kefeli U, Urakçı Z, Araz M, Arpacı E, Harputlu H, Sevinç A.

Eur Rev Med Pharmacol Sci. 2016 Apr;20(7):1238-43.

 

23. Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study.

Oruc Z, Kaplan MA, Geredeli C, Yildirim Sari N, Ozaslan E, Aytekin A, Tamer Elkiran E, Koca S, Dogan M, Turan N, Yuce O, Sevinc A, Ercelep O, Isikdogan A.

J BUON. 2020 Mar-Apr;25(2):641-647.

 

 

24. Yalcin S, Dane F, Oksuzoglu B, Ozdemir NY, Isikdogan A, Ozkan M, Demirag GG, Coskun HS, Karabulut B, Evrensel T, Ustaoglu MA, Ozdemir F, Turna H, Yavuzsen T, Aykan F, Sevinc A, Akbulut H, Yuce D, Hayran M, Kilickap S.

BMC Cancer. 2020 Mar 30;20(1):259. doi: 10.1186/s12885-020-06758-9.

 

25. Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study.

Benekli M, Gumus M, Ozkan M, Dane F, Elkiran ET, Cicin I, Sevinc A, Aliustaoglu M, Isikdogan A, Meydan N, Oksuzoglu B, Ozyilkan O, Artac M, Ozdemir F, Kilickap S.

J Oncol Pharm Pract. 2020 Oct 13:1078155220963535. doi: 10.1177/1078155220963535. Online ahead of print.

 

26. Polymorphisms in the MTHFR gene are associated with recurrence risk in lymph node-positive breast cancer patients.

Suner A, Buyukhatipoglu H, Aktas G, Kus T, Ulasli M, Oztuzcu S, Kalender ME, Sevinc A, Kul S, Camci C.

Onco Targets Ther. 2016 Sep 9;9:5603-9. doi: 10.2147/OTT.S104890. eCollection 2016.

 

27. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.

Gumus M, Bilici A, Odabas H, Ustaalioglu BBO, Kandemir N, Demirci U, Cihan S, Bayoglu IV, Ozturk T, Turkmen E, Urakci Z, Seker MM, Gunaydin Y, Selcukbiricik F, Turan N, Sevinc A.

World J Urol. 2017 Jul;35(7):1103-1110. doi: 10.1007/s00345-016-1964-6. Epub 2016 Nov 3.

 

28. Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.

Kus T, Aktas G, Kalender ME, Demiryurek AT, Ulasli M, Oztuzcu S, Sevinc A, Kul S, Camci C.

Onco Targets Ther. 2016 Aug 12;9:5073-80. doi: 10.2147/OTT.S106574. eCollection 2016.

 

29. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.

Dane F, Ozgurdal K, Yalçın Ş, Benekli M, Aykan NF, Yücel İ, Özkan M, Evrensel T, Sevinç A, Coskun HŞ, Sanli UA, Kara IO, Yumuk PF.

BMJ Open. 2020 Mar 26;10(3):e027665. doi: 10.1136/bmjopen-2018-027665.

Klinik Araştırmalar:

 30.Middle East observational study in metastatic soft tissue sarcoma: an epidemiological study on the treatment patterns (MOON).2008

31.Effectiveness an Safety of LMWH Treatment in Patients With Cancer Diagnosed With Non-High-Risk Venous Thromboembolism: Turkish Observational Study (TREBECA).2009

32.Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioquivalence study in patients with chemotherapy –induced neutropenia. 2010

33.Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 2011

 34.Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study’s primary analysis of 2573 patients.       2011